<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01053611</url>
  </required_header>
  <id_info>
    <org_study_id>2009.083</org_study_id>
    <nct_id>NCT01053611</nct_id>
  </id_info>
  <brief_title>Composite Variability Index Versus Bispectral Index (BIS)</brief_title>
  <official_title>Changes in a Composite Variability Index (CVI) and Bispectral Index (BIS) in Response to Standardized Pain Stimuli During Propofol Remifentanil Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the accuracy of the changes in CVI in response to a
      standardized noxious stimulus during various targeted pseudo-steady-state concentrations of
      remifentanil and various steady state level of BIS as guided by propofol effect compartment
      controlled TCI (closed-loop).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be allocated to receive a specific effect-site concentration of remifentanil
      and propofol. For remifentanil, concentrations will be targeted at 0, 2, 4 and 6 ng/ml. After
      an equilibration period, anesthesia will be induced in all patients using propofol in order
      to reach and maintain a BIS value of 70, 50 or 30. After an equilibration period(from start
      of propofol infusion), OAA/S will be measured in all patient. All patients will receive a
      standard pain stimulus (30 seconds, 50 mA) in order to observe the influence of the
      effect-site concentration of propofol and remifentanil on the CVI. A time window of 5 minutes
      after the stimulus will be respected to observe the changes in both BIS and CVI. After this
      period, the study will be terminated and classical maintenance of anesthesia will be
      provided.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BIS and CVI.</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Sedation During</condition>
  <arm_group>
    <arm_group_label>Group 1 BIS value 30</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 BIS value 30</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 BIS value 30</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 BIS valaue 30</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 BIS value 50</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 BIS value 50</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 BIS value 50</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 BIS value 50</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 BIS value 70</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 BIS value 70</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 BIS value 70</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 BIS value 70</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol + remifentanil 0 ng/ml</intervention_name>
    <description>remifentanil 0 ng/ml</description>
    <arm_group_label>Group 1 BIS value 30</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol + remifentanil 2 ng/ml</intervention_name>
    <arm_group_label>Group 2 BIS value 30</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol + remifentanil 4 ng/ml</intervention_name>
    <arm_group_label>Group 3 BIS value 30</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol + remifentanil 6 ng/ml</intervention_name>
    <arm_group_label>Group 4 BIS valaue 30</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol + remifentanil 0 ng/ml</intervention_name>
    <arm_group_label>Group 1 BIS value 50</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol + remifentanil 2 ng/ml</intervention_name>
    <arm_group_label>Group 2 BIS value 50</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol + remifentanil 6 ng/ml</intervention_name>
    <arm_group_label>Group 3 BIS value 50</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol + remifentanil 6 ng/ml</intervention_name>
    <arm_group_label>Group 4 BIS value 50</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol + remifentanil 0 ng/ml</intervention_name>
    <arm_group_label>Group 1 BIS value 70</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol + remifentanil 2 ng/ml</intervention_name>
    <arm_group_label>Group 2 BIS value 70</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol + remifentanil 4 ng/ml</intervention_name>
    <arm_group_label>Group 3 BIS value 70</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol + remifentanil 6 ng/ml</intervention_name>
    <arm_group_label>Group 4 BIS value 70</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA class I and II patients requiring general anesthesia for elective surgical
             procedures

        Exclusion Criteria:

          -  patient refusal

          -  weight less than 70% or more than 130% of ideal body weight,

          -  neurological disorder

          -  recent use of psycho-active medication, including alcohol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713EZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2010</study_first_submitted>
  <study_first_submitted_qc>January 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2010</study_first_posted>
  <last_update_submitted>March 24, 2011</last_update_submitted>
  <last_update_submitted_qc>March 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>M.M.R.F.Struys</name_title>
    <organization>University Medical Center Groningen</organization>
  </responsible_party>
  <keyword>composite variability index</keyword>
  <keyword>bispectral index</keyword>
  <keyword>pain</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

